I want to specifically say, I think of myself as an advocate for vulnerable populations, which is I would say, probably one in four, one in five, the people who have these eating disorder histories, people who have body image disturbance histories
Hum Mol Genet 21(17):37763784
While these pharmacovigilance findings underscore the need for heightened clinical vigilance, they represent associations rather than causal relationships, constrained by inherent limitations of FAERS such as reporting bias and confounding
MT-2 never did
If the food you are eating is metabolically destructive, modulating the response to it offers marginal benefit
Legal status (US): Tesamorelin is FDA-approved under the brand names Egrifta and Egrifta WR, manufactured by Theratechnologies, specifically to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy